| ²é¿´: 285 | »Ø¸´: 0 | |||
СÀÁÓãÓãͳæ (СÓÐÃûÆø)
|
[ÇóÖú]
thomsonÒ©Îﱨ¸æSWOTÀïµÄÄÚÈÝ
|
|
Superior viral suppression compared with Atripla (88% vs 81%), driven by improved tolerability translating to fewer dropouts in the dolutegravir-containing arm, according to the SINGLE study |
» ²ÂÄãϲ»¶
0856µ÷¼Á£¬ÊÇѧУ¾ÍÈ¥
ÒѾÓÐ5È˻ظ´
0817 »¯Ñ§¹¤³Ì 299·ÖÇóµ÷¼Á ÓпÆÑоÀú ÓжþÇøÎÄÕÂ
ÒѾÓÐ13È˻ظ´
Áº³ÉΰÀÏʦ¿ÎÌâ×é»¶ÓÄãµÄ¼ÓÈë
ÒѾÓÐ11È˻ظ´
¸´ÊÔµ÷¼Á
ÒѾÓÐ6È˻ظ´
0703»¯Ñ§µ÷¼Á £¬Áù¼¶Òѹý£¬ÓпÆÑоÀú
ÒѾÓÐ11È˻ظ´
321Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
¶«»ªÀí¹¤´óѧ»¯²Äרҵ26½ì˶ʿ²©Ê¿ÉêÇë
ÒѾÓÐ8È˻ظ´
288Çóµ÷¼Á
ÒѾÓÐ11È˻ظ´
¡¾¿¼Ñе÷¼Á¡¿»¯Ñ§×¨Òµ 281·Ö£¬Ò»Ö¾Ô¸ËÄ´¨´óѧ£¬³ÏÐÄÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
ÄÜÔ´²ÄÁÏ»¯Ñ§¿ÎÌâ×éÕÐÊÕ˶ʿÑо¿Éú8-10Ãû
ÒѾÓÐ12È˻ظ´














»Ø¸´´ËÂ¥